SCHAUMBURG, Ill. The Food and Drug Administration has approved the manufacture of three product codes of injected heparin sodium USP at APP Pharmaceuticals’ factory in Barceloneta, Puerto Rico, APP announced Monday.
The Schaumburg, Ill., company already manufactures nine products at the factory and plans to manufacture 19 million units in Puerto Rico this year.
“Bringing this third [heparin] manufacturing site online is an important part of our commitment to ensuring that an uninterrupted and safe supply of heparin of the highest quality is available for U.S. patients,” APP chief executive officer Tom Silberg said. “At the same time, we are now able to redeploy some of our manufacturing capacity at our two other facilities toward the production of other products to fulfill outstanding orders.”